GigaGen inks deal with National Cancer Institute to advance GIGA-564

3 October 2023

Barcelona, Spain-based plasma-derived medicine specialist Grifols (MCE: GRF) says that its biotech subsidiary GigaGen has signed an agreement with the National Cancer Institute (NCI), part of the USA’s National Institutes of Health (NIH), to advance development of the company’s differentiated anti-CTLA-4 antibody drug candidate for cancer treatment, GIGA-564.

The accord enables further pre-clinical and clinical studies to assess GIGA-564's potential across various tumor types, including the first in-human Phase 1 clinical trial for the drug candidate in advanced solid tumors.

Grifols acquired GigaGen in a two part deal that cost it around $115 million over 2017 and 2021.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK